A Study to Assess Adverse Events and Change in Disease Activity in Adult Participants Receiving Intravenously Infused Telisotuzumab Adizutecan Alone or With Standard of Care in Participants With Post Adjuvant Circulating Tumor DNA Positive Colorectal Cancer and No Radiographic Evidence of Disease
Recruiting · Phase 2 · NCT07023289
Conditions: Colorectal Cancer
At a glance
- Research payments reported, 2025
- $234,673
- U.S. investigators named
- 10
- Sites paid
- 7
- Planned or actual enrollment
- 140
About the trial
- Sponsor
- AbbVie
- Tested
- Telisotuzumab Adizutecan (drug), Standard of Care (drug)
- Dates
- Started 2025-09-02; completion 2029-11
- Results posted
- Not yet
Colorectal cancer (CRC) is the third most common type of cancer diagnosed worldwide. The purpose of this study is to assess change in disease activity when telisotuzumab adizutecan is given alone compared to standard of care (SOC) given alone. Telisotuzumab adizutecan is an investigational drug being developed for the treatment of CRC. This study will be divided into two groups called treatment arms. In arm 1 participants will receive telisotuzumab adizutecan alone. In arm 2 participants will receive SOC alone. Approximately 140 adult participants with CRC will be enrolled in the study in 45 sites worldwide. In arm 1, participants will receive intravenous (IV) doses of telisotuzumab adizu…
From ClinicalTrials.gov, last updated 2026-10-09. Full record, eligibility and contacts (opens in a new tab)
Industry funding
AbbVie Inc. reported $234,673 in research payments for this study in 2025 (23 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Sandra Algaze Medical Oncology · Los Angeles, CA
- David J. Park, M.D. Medical Oncology · Fullerton, CA
- Ardaman Shergill Medical Oncology · Chicago, IL
- Ravi Patel, D.O. Hospitalist · Lafayette, IN
- Eric M. Lander, MD Hematology & Oncology · Minneapolis, MN
- Spencer H. Shao, M.D. Medical Oncology · Portland, OR
- Aleksandar Jankov, MD Hematology & Oncology · Memphis, TN
- Vivian Cline, MD Medical Oncology · Round Rock, TX
- Nicholas J. Hornstein, MD, PHD Internal Medicine · Houston, TX
- Chao Yin, MD Hematology & Oncology · Fairfax, VA
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Sarah Cannon Research Institute LLC $106,300
- The University of Chicago $40,855
- University of Southern California $30,015
- Providence Medical Foundation $20,850
- Virginia Cancer Specialists PC $20,000
- Baptist Clinical Research $13,083
- Feinstein Institute for $3,570
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.